vs
金罗斯黄金（GOLD）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
金罗斯黄金的季度营收约是再鼎医药的1.2倍（$148.1M vs $127.1M），再鼎医药同比增速更快（17.1% vs -94.6%），再鼎医药自由现金流更多（$-26.7M vs $-46.6M），过去两年再鼎医药的营收复合增速更高（20.8% vs -76.2%）
金罗斯黄金公司是一家总部位于加拿大多伦多的金银开采企业，成立于1993年。目前公司共运营六座在产金矿，矿区分布在巴西、毛里塔尼亚与美国境内，在2019年InvestingNews评选的全球十大黄金开采企业中位列第五。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
GOLD vs ZLAB — 直观对比
营收规模更大
GOLD
是对方的1.2倍
$127.1M
营收增速更快
ZLAB
高出111.7%
-94.6%
自由现金流更多
ZLAB
多$19.9M
$-46.6M
两年增速更快
ZLAB
近两年复合增速
-76.2%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $148.1M | $127.1M |
| 净利润 | $11.6M | — |
| 毛利率 | 63.0% | 51.0% |
| 营业利润率 | 10.7% | -54.6% |
| 净利率 | 7.9% | — |
| 营收同比 | -94.6% | 17.1% |
| 净利润同比 | 77.4% | — |
| 每股收益（稀释后） | $0.46 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GOLDZLAB
| Q4 25 | $148.1M | $127.1M | ||
| Q3 25 | $3.7B | $115.4M | ||
| Q2 25 | $2.5B | $109.1M | ||
| Q1 25 | $3.0B | $105.7M | ||
| Q4 24 | $2.7B | $108.5M | ||
| Q3 24 | $2.7B | $101.8M | ||
| Q2 24 | $2.5B | $100.1M | ||
| Q1 24 | $2.6B | $87.1M |
净利润GOLDZLAB
| Q4 25 | $11.6M | — | ||
| Q3 25 | $-939.0K | $-36.0M | ||
| Q2 25 | $10.3M | $-40.7M | ||
| Q1 25 | $-8.5M | $-48.4M | ||
| Q4 24 | $6.6M | — | ||
| Q3 24 | $9.0M | $-41.7M | ||
| Q2 24 | $30.9M | $-80.3M | ||
| Q1 24 | $5.0M | $-53.5M |
毛利率GOLDZLAB
| Q4 25 | 63.0% | 51.0% | ||
| Q3 25 | 2.0% | 59.5% | ||
| Q2 25 | 3.3% | 60.6% | ||
| Q1 25 | 1.4% | 63.6% | ||
| Q4 24 | 1.6% | 61.5% | ||
| Q3 24 | 1.6% | 64.1% | ||
| Q2 24 | 1.7% | 64.9% | ||
| Q1 24 | 1.3% | 61.4% |
营业利润率GOLDZLAB
| Q4 25 | 10.7% | -54.6% | ||
| Q3 25 | -0.0% | -42.3% | ||
| Q2 25 | 0.5% | -50.3% | ||
| Q1 25 | -0.3% | -53.3% | ||
| Q4 24 | 0.3% | -62.6% | ||
| Q3 24 | 0.4% | -66.6% | ||
| Q2 24 | 1.3% | -76.0% | ||
| Q1 24 | 0.2% | -80.7% |
净利率GOLDZLAB
| Q4 25 | 7.9% | — | ||
| Q3 25 | -0.0% | -31.2% | ||
| Q2 25 | 0.4% | -37.3% | ||
| Q1 25 | -0.3% | -45.8% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.3% | -40.9% | ||
| Q2 24 | 1.2% | -80.2% | ||
| Q1 24 | 0.2% | -61.4% |
每股收益（稀释后）GOLDZLAB
| Q4 25 | $0.46 | $-0.05 | ||
| Q3 25 | $-0.04 | $-0.03 | ||
| Q2 25 | $0.43 | $-0.04 | ||
| Q1 25 | $-0.36 | $-0.04 | ||
| Q4 24 | $0.27 | $-0.09 | ||
| Q3 24 | $0.37 | $-0.04 | ||
| Q2 24 | $1.29 | $-0.08 | ||
| Q1 24 | $0.21 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.8M | $715.5M |
| 总资产 | $3.8B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GOLDZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
股东权益GOLDZLAB
| Q4 25 | $653.8M | $715.5M | ||
| Q3 25 | $644.0M | $759.9M | ||
| Q2 25 | $649.5M | $791.7M | ||
| Q1 25 | $643.6M | $810.8M | ||
| Q4 24 | $612.7M | $840.9M | ||
| Q3 24 | $611.1M | $667.7M | ||
| Q2 24 | $607.6M | $704.2M | ||
| Q1 24 | $583.2M | $762.2M |
总资产GOLDZLAB
| Q4 25 | $3.8B | $1.2B | ||
| Q3 25 | $2.6B | $1.2B | ||
| Q2 25 | $2.2B | $1.2B | ||
| Q1 25 | $2.2B | $1.2B | ||
| Q4 24 | $1.9B | $1.2B | ||
| Q3 24 | $2.0B | $985.3M | ||
| Q2 24 | $1.8B | $987.4M | ||
| Q1 24 | $1.7B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-42.6M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $-46.6M | $-26.7M |
| 自由现金流率自由现金流/营收 | -31.5% | -21.0% |
| 资本支出强度资本支出/营收 | 2.7% | 0.5% |
| 现金转化率经营现金流/净利润 | -3.66× | — |
| 过去12个月自由现金流最近4个季度 | $310.3M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流GOLDZLAB
| Q4 25 | $-42.6M | $-26.0M | ||
| Q3 25 | $195.4M | $-32.0M | ||
| Q2 25 | $67.0M | $-31.0M | ||
| Q1 25 | $102.8M | $-61.7M | ||
| Q4 24 | $110.1M | $-55.8M | ||
| Q3 24 | $-127.5M | $-26.8M | ||
| Q2 24 | $82.8M | $-42.2M | ||
| Q1 24 | $79.8M | $-90.1M |
自由现金流GOLDZLAB
| Q4 25 | $-46.6M | $-26.7M | ||
| Q3 25 | $193.4M | $-35.0M | ||
| Q2 25 | $63.1M | $-33.9M | ||
| Q1 25 | $100.4M | $-63.2M | ||
| Q4 24 | $106.4M | $-58.4M | ||
| Q3 24 | $-128.1M | $-28.2M | ||
| Q2 24 | $80.1M | $-42.9M | ||
| Q1 24 | $79.1M | $-91.1M |
自由现金流率GOLDZLAB
| Q4 25 | -31.5% | -21.0% | ||
| Q3 25 | 5.3% | -30.4% | ||
| Q2 25 | 2.5% | -31.1% | ||
| Q1 25 | 3.3% | -59.9% | ||
| Q4 24 | 3.9% | -53.8% | ||
| Q3 24 | -4.7% | -27.7% | ||
| Q2 24 | 3.2% | -42.9% | ||
| Q1 24 | 3.0% | -104.5% |
资本支出强度GOLDZLAB
| Q4 25 | 2.7% | 0.5% | ||
| Q3 25 | 0.1% | 2.6% | ||
| Q2 25 | 0.2% | 2.6% | ||
| Q1 25 | 0.1% | 1.5% | ||
| Q4 24 | 0.1% | 2.4% | ||
| Q3 24 | 0.0% | 1.3% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 0.0% | 1.1% |
现金转化率GOLDZLAB
| Q4 25 | -3.66× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 6.49× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 16.78× | — | ||
| Q3 24 | -14.20× | — | ||
| Q2 24 | 2.68× | — | ||
| Q1 24 | 15.91× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GOLD
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
